{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T19:36:04Z","timestamp":1782502564882,"version":"3.54.5"},"reference-count":11,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To minimize confounding factors, we aimed to describe the changes in weight and body mass index (BMI) following the single substitution of tenofovir disoproxil fumarate (TDF) by tenofovir alafenamide (TAF) in people living with HIV (PLWH).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We designed a retrospective study in a large French cohort. We included all HIV\u2010suppressed adults under TDF\u2009+\u2009emtricitabine\u2009+\u2009rilpivirine or elvitegravir\/cobistat, who experienced a first switch from TDF to TAF, while other antiretrovirals remained unchanged (Switch group). We compared this population to a propensity score\u2010matched Control group (1:1) who stayed on the same TDF\u2010based regimen. Changes were evaluated after 6 (M6) and 12\u2009months (M12).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Some 1260 and 468 PLWH were evaluable per group at M6 and M12, respectively. In the Switch group, there was a mean (95% confidence interval [95% CI]) weight gain of +1014\u2009g (+826 to +1201) at M6 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) and +1365\u2009g (+910 to +1820) at M12 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), as compared with baseline. Meanwhile, there was no significant weight gain at M6 (+139\u2009g [\u221250 to +328]) and M12 (\u221232\u2009g [\u2212413 to +350]) in the matched Control group. Similarly, mean BMI increased significantly in the Switch group at M6 (+0.35, 95% CI: +0.29 to +0.41, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) and M12 (+0.49, 95% CI: +0.32 to +0.65, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), while it was stable at M6 (+0.05, 95% CI: \u22120.01 to +0.12, <jats:italic>p<\/jats:italic>\u2009=\u20090.11) and M12 (+0.01, 95% CI: \u22120.12 to +0.14, <jats:italic>p<\/jats:italic>\u2009=\u20090.89) in the No Switch group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Although modest, there is a significant weight gain following the substitution of TDF by TAF. This should be anticipated in certain at\u2010risk populations.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.13488","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T02:59:06Z","timestamp":1680663546000},"page":"925-932","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Weight gain following the single substitution of tenofovir disoproxil fumarate by tenofovir alafenamide in <scp>HIV<\/scp>\u2010infected people from the French Dat'<scp>AIDS<\/scp> cohort: A propensity score\u2010matched analysis"],"prefix":"10.1111","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2264-4822","authenticated-orcid":false,"given":"Laurent","family":"Hocqueloux","sequence":"first","affiliation":[{"name":"Centre Hospitalier Universitaire d'Orl\u00e9ans  Orl\u00e9ans France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Menard","sequence":"additional","affiliation":[{"name":"IHU \u2010 M\u00e9dit\u00e9rran\u00e9e Infection  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Arvieux","sequence":"additional","affiliation":[{"name":"CHU de Rennes  Rennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Joly","sequence":"additional","affiliation":[{"name":"Bichat\u2010Claude Bernard University Hospital  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Becker","sequence":"additional","affiliation":[{"name":"Croix\u2010Rousse Hospital, Hospices Civils de Lyon  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Ch\u00e9ret","sequence":"additional","affiliation":[{"name":"APHP, H\u00f4pital Bic\u00eatre  Le Kremlin\u2010Bic\u00eatre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudine","family":"Duvivier","sequence":"additional","affiliation":[{"name":"APHP, Necker\u2010Pasteur Infectiology Center University Paris Cit\u00e9, INSERM U1016, CNRS UMR8104, Institut Cochin, IHU Imagine  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Cabi\u00e9","sequence":"additional","affiliation":[{"name":"Martinique University Hospital  Fort\u2010de\u2010France France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Delpierre","sequence":"additional","affiliation":[{"name":"CERPOP, Universit\u00e9 de Toulouse, Inserm, UPS  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clotilde","family":"Allavena","sequence":"additional","affiliation":[{"name":"CHU de Nantes  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Dat'AIDS Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902824"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz999"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-018-1227-0"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002496"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25702"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/nqaa336"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw323"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101412"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac621"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells11111841"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003083"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13488","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:59:02Z","timestamp":1692320342000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.13488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":11,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1111\/hiv.13488"],"URL":"https:\/\/doi.org\/10.1111\/hiv.13488","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,4]]},"assertion":[{"value":"2022-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}